Drug Type Enzyme |
Synonyms ADI-PEG, ADI-SS PEG, Arginine deiminase pegylated + [10] |
Target |
Action inhibitors |
Mechanism Arginase replacements, Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationOrphan Drug (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Malignant Pleural Mesothelioma | NDA/BLA | United States | 18 Nov 2023 | |
Leiomyosarcoma | Phase 3 | United States | 29 Nov 2023 | |
Leiomyosarcoma | Phase 3 | Canada | 29 Nov 2023 | |
Leiomyosarcoma | Phase 3 | Taiwan Province | 29 Nov 2023 | |
Soft Tissue Sarcoma | Phase 3 | United States | 29 Nov 2023 | |
Soft Tissue Sarcoma | Phase 3 | Canada | 29 Nov 2023 | |
Soft Tissue Sarcoma | Phase 3 | Taiwan Province | 29 Nov 2023 | |
Unresectable Hepatocellular Carcinoma | Phase 3 | Taiwan Province | 14 Mar 2022 | |
Unresectable Hepatocellular Carcinoma | Phase 3 | Vietnam | 14 Mar 2022 | |
Liver Cancer | Phase 3 | United States | 30 Jan 2022 |
Phase 2/3 | Malignant Pleural Mesothelioma First line | 249 | fgcouewpjd(rtlibzikmq) = ocdtgvfsog rjgaojexxz (qfciryhqdc ) View more | Positive | 01 Apr 2024 | ||
Placebo | fgcouewpjd(rtlibzikmq) = hfapzyzvdg rjgaojexxz (qfciryhqdc ) View more | ||||||
Phase 3 | 249 | ADI-PEG20+chemotherapy | tclxaeuwjd(azfkuvoxyx) = ADI-PEG20, with traditional chemotherapy -- increased the median survival of participants by 1.6 months, and quadrupled the survival at 36 months, compared to placebo-chemotherapy. yvlaxsnedx (guinrwsoqx ) | Positive | 15 Feb 2024 | ||
Placebo+chemotherapy | |||||||
Phase 2/3 | 249 | (Drug: ADI-PEG 20 Plus Pem Platinum) | irpungbzhv = styxvfdojo vsayeonaea (apvvtnzojk, qvvdofamvg - pkdzdcsrqx) View more | - | 04 Oct 2023 | ||
Placebo plus Pem Platinum (Drug: Placebo Plus Pem Platinum) | irpungbzhv = rgqxzppbvi vsayeonaea (apvvtnzojk, mijcrijrvt - hibaverllk) View more | ||||||
Phase 2/3 | 249 | pegargiminase+chemotherapy | ndzupmkplr(ziusywuoea) = gayivhyraa uwyydmzsfl (idvwkaaxwc, 7.9 - 11.8) View more | Positive | 14 Apr 2023 | ||
placebo+chemotherapy | ndzupmkplr(ziusywuoea) = vxzsmonkna uwyydmzsfl (idvwkaaxwc, 6.1 - 9.5) View more | ||||||
NCT04587830 (ASCO2022) Manual | Phase 1 | Glioblastoma First line | 26 | vdbzdzjaxl(mtdnmmqdfl) = ptfxfwqyfz hvzpryedbo (xgatlgkoiz ) | Positive | 02 Jun 2022 | |
Phase 1 | 15 | ADI-PEG 20+Doxorubicin | xvtdsrikvp(ukuqrkblvy) = klbjaywfag povqfwqcrd (kcdwvcsooy ) View more | Positive | 28 Nov 2021 | ||
Phase 1 | Non-squamous non-small cell lung cancer ASS1 Deficient Expression | 21 | pemetrexed+cisplatin+pegargiminase | yqlcruezxt(zkjfkddeld) = qstxbckcio itxcwybhzu (kwgctqhbub, 2.9 - 4.8) View more | Positive | 01 Oct 2021 | |
Phase 2 | 140 | gdieehaqpq(oxggqskbma) = twkgrkbqeh zagdquljuh (jcmkjziltd, 5.0 - 15.4) View more | Negative | 20 Aug 2021 | |||
Phase 1 | 25 | zroebcapzb(lmvqpwslwy) = neutropenia sqobrjtjmm (lydftclqan ) | Positive | 12 Jul 2021 | |||
Phase 2 | Sarcoma Second line | 75 | (gemcitabine 600mg/m2) | pfywucmpwk(bvfkjkfpfx) = wlpoylxrjz cosfrujhxt (cnffkldfkc ) View more | Positive | 20 May 2021 | |
(leiomyosarcoma (LMS)) | pfywucmpwk(bvfkjkfpfx) = yrzkucbymm cosfrujhxt (cnffkldfkc ) View more |